IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 17,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $154.54, for a total transaction of $2,627,180.00. Following the sale, the chairman now owns 1,039,034 shares in the company, valued at approximately $160,572,314.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jonathan W. Ayers also recently made the following trade(s):
- On Tuesday, August 8th, Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock. The stock was sold at an average price of $155.22, for a total transaction of $2,793,960.00.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down 2.23% during mid-day trading on Thursday, hitting $151.06. 912,673 shares of the company were exchanged. The stock’s 50-day moving average price is $162.05 and its 200 day moving average price is $155.37. The stock has a market cap of $13.18 billion, a PE ratio of 51.96 and a beta of 0.49. IDEXX Laboratories, Inc. has a 12-month low of $102.45 and a 12-month high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The company had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. During the same period in the prior year, the business earned $0.74 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post $3.18 EPS for the current fiscal year.
IDEXX Laboratories announced that its board has authorized a stock repurchase plan on Wednesday, May 3rd that allows the company to repurchase 3,000,000 shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
Large investors have recently bought and sold shares of the stock. Bronfman E.L. Rothschild L.P. boosted its stake in IDEXX Laboratories by 2.3% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 770 shares of the company’s stock valued at $119,000 after buying an additional 17 shares in the last quarter. Capital Advisors Ltd. LLC acquired a new stake in IDEXX Laboratories during the second quarter valued at $128,000. Acrospire Investment Management LLC boosted its stake in IDEXX Laboratories by 496.5% in the first quarter. Acrospire Investment Management LLC now owns 841 shares of the company’s stock valued at $130,000 after buying an additional 700 shares in the last quarter. Global X Management Co. LLC boosted its stake in IDEXX Laboratories by 44.6% in the first quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock valued at $162,000 after buying an additional 323 shares in the last quarter. Finally, Flagship Harbor Advisors LLC acquired a new stake in IDEXX Laboratories during the first quarter valued at $200,000. 89.80% of the stock is owned by institutional investors.
A number of brokerages recently issued reports on IDXX. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Wednesday, August 2nd. BidaskClub lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Friday, July 28th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a research note on Wednesday, July 19th. Finally, Canaccord Genuity restated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, June 13th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $173.80.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.